Most Read Articles
Saras Ramiya, 5 days ago
Accord Healthcare launches Accord Bortezomib® (bortezomib 3.5 mg per vial) for the treatment of patients with multiple myeloma and mantle cell lymphoma in Malaysia.
Dr. Alexander Drilon, 19 Jul 2017
With the dramatic evolution of sequencing technology and emergence of effective targeted therapies, using a comprehensive molecular approach to guide treatment decisions is becoming more accessible and applicable in the clinic. At the recent Foundation Medicine meeting in Hong Kong, Dr Alexander Drilon, clinical director of the Early Drug Development Service at Memorial Sloan Kettering Cancer Center (MSKCC), New York, US, discussed the current landscape and potential benefits of comprehensive molecular profiling in non-small cell lung cancer (NSCLC).
31 Jan 2017
At the launch of Caris Molecular Intelligence® in Malaysia, Dr Andrew Dean, Head of Oncology at the St John of God Subianco Hospital, Perth, shared with the audience on molecular profiling and its benefits, with a focus on the Caris Molecular Intelligence® service.
Su Ping Chuah, 01 Aug 2014

New immune therapies with new targets that can induce long-term remission in patients with advanced cutaneous T-cell lymphoma (CTCL) are needed, says an expert.

Accord Healthcare launches treatment for multiple myeloma, mantle cell lymphoma

Saras Ramiya
5 days ago
The Accord Healthcare team at the launch of Accord Bortezomib in Kuala Lumpur

Accord Healthcare launches Accord Bortezomib® (bortezomib 3.5 mg per vial) for the treatment of patients with multiple myeloma and mantle cell lymphoma in Malaysia.

“Accord Healthcare has been given the privilege to market this product looking at the various benefits patients as well as healthcare providers can gain from this product,” said Paul Andrew, business development manager – Malaysia, Accord Healthcare Sdn Bhd, at the launch in Kuala Lumpur recently.

“We have incorporated PharmaShield® technology in bortezomib vials for healthcare professionals’ safety. The technology is a superficial plastic sheath around the vial that covers [the vial] from the reinforced non-PVC base to the vial seal at the top,” said Venkata Kalyan Vadlamudi, senior manager marketing and business development, corporate office, Accord Healthcare.

The PharmaShield packing prevents leakage even if the vial accidentally drops or breaks during transport so healthcare professionals are not exposed to the cytotoxic fumes. The reinforced non-PVC base is shock absorbent when the vial accidentally drops, he added.

Bortezomib have been commercialized for the past 3 years in various markets across the globe with supplies of 200,000 vials, said Venkata.

Based on the World Health Organization (WHO) report in 2014, 6.3 percent of the cancer patients in Malaysia had multiple myeloma and lymphomas. [Available at www.who.int/cancer/country-profiles/mys_en.pdf Accessed on 14 November]

“The availability of Accord Bortezomib is expected to reduce the financial burden for patients and their families and make the treatment process easier for healthcare providers. We hope that Accord Healthcare is given the chance to assist our nation in the expansion of treatment to cover more cancer patients especially those with multiple myeloma,” said Andrew.

“Accord Healthcare is committed in providing quality generic medicines to the Malaysian population. There are more products coming your way in the next few months as well as in the next couple of years. We look forward to working closely with [healthcare professionals] in providing affordable medicines to the Malaysian population,” said Ms Koh Oon Sim, regional director, Accord Healthcare.

Accord was incepted in the UK in 2008 and currently it’s a completely vertical integrated company owning active pharmaceutical ingredient (API), manufacturing, supply, marketing, sales, regulatory and pharmacovigilance departments, said Venkata.

Currently, Accord Healthcare caters to 70 countries with their oncology range of products. The company has 35 molecules in oncology, which have been commercialized and many more in the pipeline including the biosimilars, according to Venkata.

Furthermore, their manufacturing plants have been audited and inspected by world renowned regulatory authorities including the US Food and Drug Administration (FDA), UK Medicines and Healthcare products Regulatory Agency (MHRA), Therapeutic Goods Administration (TGA) of Australia, National Health Surveillance Agency (ANVISA) of Brazil, Gulf Corporation Council (GCC), Medicines Control Council (MCC), and Health Canada, he said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Saras Ramiya, 5 days ago
Accord Healthcare launches Accord Bortezomib® (bortezomib 3.5 mg per vial) for the treatment of patients with multiple myeloma and mantle cell lymphoma in Malaysia.
Dr. Alexander Drilon, 19 Jul 2017
With the dramatic evolution of sequencing technology and emergence of effective targeted therapies, using a comprehensive molecular approach to guide treatment decisions is becoming more accessible and applicable in the clinic. At the recent Foundation Medicine meeting in Hong Kong, Dr Alexander Drilon, clinical director of the Early Drug Development Service at Memorial Sloan Kettering Cancer Center (MSKCC), New York, US, discussed the current landscape and potential benefits of comprehensive molecular profiling in non-small cell lung cancer (NSCLC).
31 Jan 2017
At the launch of Caris Molecular Intelligence® in Malaysia, Dr Andrew Dean, Head of Oncology at the St John of God Subianco Hospital, Perth, shared with the audience on molecular profiling and its benefits, with a focus on the Caris Molecular Intelligence® service.
Su Ping Chuah, 01 Aug 2014

New immune therapies with new targets that can induce long-term remission in patients with advanced cutaneous T-cell lymphoma (CTCL) are needed, says an expert.